- A total of 27 abstracts reinforce AbbVie leadership in advancing research and the standards of care across multiple gastroenterological conditions, including inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS)
- Presentations include further analyses of Phase 3 clinical study programs for RINVOQ® (upadacitinib) in moderately to severely active ulcerative colitis and investigational use of risankizumab in moderately to severely active Crohn’s disease
AbbVie (NYSE: ABBV) today announced that 27 abstracts across its gastroenterology portfolio will be presented at the Digestive Disease Week (DDW) Annual Meeting, May 21-24, 2022, in San Diego and virtually.
AbbVie’s research to be presented at DDW 2022 addresses digestive and inflammatory bowel diseases, including ulcerative colitis (UC), Crohn’s disease (CD), and irritable bowel syndrome with constipation (IBS-C) / chronic idiopathic constipation (CIC).
“Since establishing our commitment to gastroenterology 15 years ago, our presence at DDW has grown continuously as our portfolio has expanded,” said Celine Goldberger M.D., Ph.D., vice president, head of US medical affairs, AbbVie. “We are proud to present data on a range of digestive conditions across our portfolio and pipeline. AbbVie’s commitment to GI and IBD patients remains strong, and we are looking forward to connecting again with the gastroenterology community at DDW this year.”
AbbVie will share oral presentations from two assets, RINVOQ® (upadacitinib) and LINZESS® (linaclotide). Notably, a late-breaking oral presentation will focus on the efficacy and safety of upadacitinib in adult patients with moderately to severely active Crohn’s disease who have failed prior biologics. Additional RINVOQ oral presentations will include analyses from the pivotal Phase 3 trials (U-ACHIEVE induction and U-ACCOMPLISH) of RINVOQ in adults with moderately to severely active UC, including data evaluating changes in ulcerative colitis symptoms one day after treatment, and data on patients who received an extended induction phase prior to maintenance treatment. An oral presentation will also address an evaluation of patients’ threshold for meaningful improvement based on the novel abdominal score outcome measure in adult patients with IBS-C for LINZESS.
A database with all AbbVie abstracts accepted for presentation at DDW 2022 can be found here. Notable poster data will be on display from May 22-24 from 12:30-1:30 PM PT, including efficacy and safety data from Phase 3 studies of risankizumab in moderately to severely active Crohn’s disease, and Phase 2 investigational data evaluating linaclotide in children two to five years old with functional constipation.
The details of AbbVie’s oral presentations at DDW 2022 are outlined below.
| Abstract Title | Presentation DetailsAll times PDT |
| Ulcerative Colitis (UC) | |
| Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active ulcerative colitis | Oral presentation; Controlled IBD Trials 2: Small Molecules; May 24; 10:15 AM to 10:30 AM |
| Upadacitinib therapy reduces ulcerative colitis symptoms within day 1 of treatment onset | Oral presentation; Controlled IBD Trials 2: Small Molecules; May 24; 10:30 AM to 10:45 AM |
| Crohn’s Disease (CD) | |
| Efficacy and safety of upadacitinib induction therapy in patients with moderately to severely active Crohn’s disease who failed prior biologics: results from a randomized phase 3 U-EXCEED study | Oral Presentation; Late-Breaking Clinical Science Abstract Plenary; May 24; 9:15 AM to 9:30 AM |
| Irritable Bowel Syndrome with Constipation (IBS-C) | |
| Patient-derived meaningful change thresholds in the novel abdominal score outcome measure in irritable bowel syndrome with constipation | Oral presentation; New Concepts In Diseases of the Colon & Rectum; May 21; 3:00-3:15 PM |
SKYRIZI® is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization of SKYRIZI globally. Use of risankizumab in Crohn’s disease is not approved and its safety and efficacy have not been evaluated by regulatory authorities.
LINZESS is part of a collaboration between AbbVie and Ironwood Pharmaceuticals to share development and commercialization of LINZESS in the United States.
About Digestive Disease Week®
Digestive Disease Week (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and virtual meeting from May 21-24, 2022. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.
About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across our Allergan Aesthetics portfolio.
Source link:https://news.abbvie.com/
